CytoHub Inc., a San Diego-based biotechnology company founded in 2023, is revolutionizing cardiac health research with its innovative CardioVive™ platform. Leveraging the unparalleled accuracy of human mini hearts, CytoHub offers a groundbreaking approach to cytotoxicity screening, disease modeling, and drug discovery.

The company’s cutting-edge technology enables the creation of highly accurate and physiologically relevant human heart models, providing invaluable insights into cardiac function, disease progression, and therapeutic efficacy. By combining these advanced models with AI-powered data analysis, CytoHub is able to deliver intelligent drug development services and groundbreaking therapeutic solutions efficiently and effectively.

CytoHub’s mission is to improve human health by supporting the development of innovative treatments for heart diseases. With its commitment to scientific excellence and a focus on patient outcomes, CytoHub is poised to make a significant impact on the future of cardiac care.